Hemostemix Inc. is a clinical-stage biotechnology company focused on developing autologous cell therapies for vascular and ischemic diseases. Its primary investigational product, ACP-01 (Angiogenic Cell Precursors), is derived from a patient's own blood and aims to promote new blood vessel formation and tissue repair. Hemostemix conducts Phase I and II clinical trials for various conditions, including critical limb ischemia, ischemic cardiomyopathy, and vascular dementia. The company operates within the fields of clinical research, cellular biology, and manufacturing, with a commitment to ethical research and regulatory compliance.
- Website
- www.hemostemix.com
- Issuer profile
- All listings